Caffeine Topical Gel Formulation

Main Article Content

Thanaporn Amnualkit
Suthimaln Ingkatawornwong
Duangkhae Maneenuan
Kittichote Worachotekamjorn

Abstract

Caffeine was used topically as one of many ingredients in various cosmetic preparations for reducing under-eye puffiness and dark circles. Gels containing 3% w/w caffeine as an active ingredient were prepared in this study. Suitable co-solvent systems and gel-forming concentrations were studied. Their effects on caffeine release from formulation were also studied. Suitable gel formulations consisted of carbopol Ultrez-21 as a gel-forming agent and propylene glycol (PG) as a co-solvent. The result showed that the increased concentration of Carbopol Ultrez-21, affected the formulation and thereby giving higher viscosity. However, all concentrations Carbopol Ultrez-21 studied (0.2%, 0.5%, 1%, 2% and 4%) did not affect caffeine release significantly. The percentage of PG in the formulation greatly affected caffeine release. Formulation containing 15% and 30% w/w PG gave release rate from Higuchi’s equation of 2.47 ± 0.26 mg/cm²/h½ and 2.37 ± 0.17 mg/cm²/h½, respectively which were lower when compared to release rate of 2.67 ± 0.07 mg/cm²/h½ from formulation containing 7.5% w/w PG. The best formulation of caffeine gel with good physical appearance and good release rate comprised of 3% caffeine, 0.5% carbopol Ultrez-21 and 7.5% PG.

Downloads

Download data is not yet available.

Article Details

Section
Pharmacy

References

Amnuaikit c, Ikeuchi I, Ogawara K, et al. 2005. Skin permeation of propranolol from polymeric film containing terpene enhancers for transdermal use. Inf J Pharm 289(2); 167-178.

Barry, BW. 1983. Dermatological formulations: percutaneous absorption, Marcel Dekker, New York.

Bonacucma, G, Cespi, M, Misici-Falzi, M, Palmieri, GF. 2006. Rheological, adhesive and release characterization of semisolid

Carbopol/tetraglycol systems. Int J Pharm 307(1): 129-140.

Chu, JS, Yu, DM, Amidon, GL, et al. 1992. Viscoelastic properties of polyacrylic acid gels in mixed solvents. Pharm Res 9: 1659-1663.

Collett, JH, Tobin, EA. 1979. Relationships between poloxamer structure and the solubilization of some para-substituted acetanilides. J Pharm Pharmacol 31: 174-177.

Dias, M, Farinha, A, Faustino, E, et al. 1999. Topical delivery of caffeine from some commercial formulations. Int J Pharm 182: 41-47.

Dreher, F, Fouchard, F, Patouillet, c, et al. 2002. Comparison of cutaneous bioavailability of cosmetic preparations containing caffeine or alpha-tocopherol applied on human skin models or human skin ex vivo at finite dose. Skin Pharmocol Physiol 15suppl. 1: 40-58.

Knight, D, Wilkinson, R, Hughes, B, et al. 2003. Caffeine Pharmacology, viewed, http://www.adhb.qovt.nz/newborn/DruqProtocols/caffeinePharrnacoloQy.htm Accessed March 22, 2006.

Motoyoshi, K, Nozawa, S, Yoshimura, M, et al. 1984. The safety of propylene glycol and other humectants. Cosmet Toilet 99(10); 83-91.

Reynolds, JEF. 1993. Caffeine; Martindale The Extra Pharmacopoeia 30^ed. 1 The pharmaceutical press, London: pp.1315.

Schmolka, IR. 1967. Applications of pluronic polyols in the cosmetic industry. Am Perfum Cosmet 82(7): 25-30.

Secard, DL. 1962. Carbopol pharmaceuticals. Drug Cosmet Ind 90(1): 28-30, 113-116.